Pharmaceuticals, Biotechnology and Life Sciences
Mylan is potentially getting access to 14 indications after approval, as first neurotoxin formulation to be developed as a potential biosimilar product to BOTOX.
Revance, Mylan Biosimilar to Botox postpon program decision to aftr April
Allergan said Thursday that the U.S. FDA approved its supplemental Biologics License Application (sBLA) for Botox for the treatment younger patients with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP).
NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications,…
Allergan’s net revenue for the fourth quarter 2016 rose 7 percent to $3.86 billion, mostly driven by better sales of Botox, Linzess and certain other new products.
Two-decade Pfizer mission pays off for Gueggenheim’s deal king
Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion (£106 billion) to slash its U.S. tax bill, rekindling a fierce political debate over the financial manoeuvre.
“These findings may help inform specialists treating patients with overactive bladder, that BOTOX is an effective and safe treatment option for patients not getting the relief from an anticholinergic.”